Theraclone Sciences

Discovering human monoclonal antibodies for safe and effective therapeutic product development

placeSeattle, Washington, United States calendar_todayFounded 2004 groups19 employees language theraclone-sciences.com

Registered entities

Innovation

23 patent families (12 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace steady. Cited 6,646 times.

YearFilings
201514
20168
20173
20182
20193
20202
20212
20222
20232
20242
20252
20262

Investor mix

9 investors on record; lead investors include Arch Venture Partners, Healthcare Ventures, Alexandria, Versant Ventures.

Investor typeCountShare
Venture capital556%
Bank & private debt111%
Other / undisclosed333%
Coming soon